Burning Rock Biotech Limited (BNR)

Market Cap	61.05M
Revenue (ttm)	72.11M
Net Income (ttm)	-32.88M
Shares Out	10.77M
EPS (ttm)	-3.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,461
Open	5.70
Previous Close	5.76
Day's Range	5.31 - 6.03
52-Week Range	2.18 - 9.48
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2025

About BNR

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cance...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 674
• Stock Exchange: NASDAQ
• Ticker Symbol: BNR
• Website: https://www.brbiotech.com

Financial Performance

In 2024, Burning Rock Biotech's revenue was 515.82 million, a decrease of -4.02% compared to the previous year's 537.44 million. Losses were -346.63 million, -46.97% less than in 2023.

Financial numbers in CNY